期刊文献+

重组人p53腺病毒在乳腺癌裸鼠体内耐药逆转作用及其对P-糖蛋白表达的影响

Effect of adenovirus-mediated p53 gene therapy on reversing multidrug resistance in breast cancer in vivo and its effect on expression of P-gp
下载PDF
导出
摘要 目的研究重组人p53腺病毒(rAd-p53)对人乳腺癌MCF-7/ADR裸鼠移植瘤的耐药逆转作用及其对耐药相关P-糖蛋白(P-glycoprotein,P-gp)表达的影响。方法建立人乳腺癌MCF-7/ADR裸鼠耐药模型,随机分为对照组、rAd-p53组、阿霉素组、联合组,分别给予不同治疗。观察裸鼠肿瘤体积的变化,western blot检测P-gp蛋白表达情况。结果成瘤后rAdp53组、阿霉素组、联合组抑瘤率分别为42.05%、49.21%、69.97%,各治疗组体积与对照组相比差异有统计学意义(P<0.05),且联合组显著优于rAd-p53组和阿霉素组(P<0.05)。对照组、rAd-p53组、阿霉素组、联合组P-gp表达水平分别为(0.5964±0.0806)、(0.5506±0.0127)、(0.5641±0.0055)、(0.4652±0.0982),联合组P-gp表达水平低于其他各组。结论 Ad-p53对人乳腺癌阿霉素耐药细胞株MCF-7/ADR建立的裸鼠移植瘤具有多药耐药的逆转作用,并可下调P-gp的表达。 Objective To study the effect of recombinant adenovirus mediated p53 gene on reversing multidrng resistance and expression of P-gp in MCF-7/ADR human breast cancer xenografts. Methods MCF-7/ADR human breast cancer cells were injected into nude mice. The experimental mice with xenografts were randomized into groups of control, rAd-p53, adriamycin, rAd-p53 + adria- mycin. The growth of tumor was observed. Expression of P-gp in several groups was assessed by Western blotting. Results The inhib- itory rate after administration of rAd-p53, adriamycin, and rAd-p53 + adriamyein were 42.05% ,49.21%, and 69.97%, respectively. There was significant difference between all treatment groups and control group ( P 〈 0.05 ). And inhibition in group rAd-p53 + adria- mycin was more significant than inhibition in group rAd-p53 and group adriamycin. The expression of P-gp in groups of control, rAd- p53, adriamyein, rAd-p53 + adriamycin were (0. 5964± 0. 0806 ), ( 0. 5506 ± O. 0127 ), ( 0. 5641±0. 0055 ), and ( 0. 4652 ± 0. 0982), respectively it was decreased significantly in group rAd-p53 + Adriamycin. Conclusions tAd-p53 can effectively reverse the multidrng resistance of MCF-7/ADR xenografts in nude mice. And it can inhibit the expression of P-gp.
出处 《武警医学》 CAS 2014年第4期376-378,382,共4页 Medical Journal of the Chinese People's Armed Police Force
关键词 乳腺癌 p53基因 多药耐药 P-糖蛋白 breast cancer P53 gene multidrng resistance P-glycoprotein
  • 相关文献

参考文献1

二级参考文献11

  • 1戚晓东,杨之斌,韩德民,倪鑫,牛旗,李志新,姜乃佳.“今又生”治疗晚期恶性肿瘤的疗效观察(附23例)[J].现代肿瘤医学,2006,14(10):1295-1297. 被引量:19
  • 2Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res, 1996,56:892-898.
  • 3Plumb JA. Cell sensitivity assays: the MTT assay. Methods Mol Med, 2004,88 : 165-169.
  • 4Trock B J, Leonessa F, Clarke R, et al. Multidrug resistance in breast cancer: a meta-analysis of MDRI/P-gp expression and its possible functional significance. J Natl Cancer Inst, 1997,89:917- 931.
  • 5Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control,2003, 10 : 159-165.
  • 6范文红.抑癌基因与人类肿瘤.詹启敏主编.分子肿瘤学.北京:人民卫生出版社,2005.118-119.
  • 7Bush JA, Li G. Cancer chemoresistance:the relationship between 163 and multidrug transporters. Int J Cancer, 2002,98:323-330.
  • 8Horio Y, Hasegawa Y, Sekido Y, et al. Synergistic effect s of adenovirus expressing wild type p53 on chemosensitivity of non- small cell lung cancer cells. Cancer Gene Ther,2000,7:537-544.
  • 9Wolf JK, Bodurka DC, Gano JB, et al. A phase Ⅰ studay of Ad- p53 (ngn 201; ADVEXIN ) for patients with platinum and paclitaxel resistant epithelial ovarian cancer. Gynecol Oncol, 2004,94:442-448.
  • 10Baek JH, Agarwalm L, Tubbs RR, et al. In vivo recombinant Adenovirus mediated p53 gene therapy in a syngeneic rat model for colorectal cancer. J Korean Med Sci, 2004,19:834-841.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部